About Abivax SA - American Depositary Shares (ABVX)
Abivax SA is a biopharmaceutical company that focuses on the development of innovative therapeutics to treat inflammatory diseases and certain viral infections. The company is primarily engaged in research and development of its proprietary product candidates, leveraging its unique platform technologies to discover and optimize treatments. Abivax aims to address significant unmet medical needs through the advancement of its drug candidates into clinical trials, with a strong emphasis on developing solutions that improve patient outcomes and quality of life. Read More
Gainers Abivax (NASDAQ:ABVX) shares increased by 36.0% to $130.74 during Tuesday's pre-market session. The company's market cap stands at $7.6 billion. Cuprina Holdings (Cayman) (NASDAQ:CUPR) shares moved
LOS ANGELES, June 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abivax S.A. (“Abivax” or “the Company”) (NASDAQ: ABVX) for violations of the securities laws.
LOS ANGELES, June 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abivax S.A. (“Abivax” or “the Company”) (NASDAQ: ABVX) for violations of the securities laws.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abivax S.A. (“Abivax” or “the Company”) (NASDAQ: ABVX) for violations of the securities laws.
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
